<DOC>
	<DOCNO>NCT00512928</DOCNO>
	<brief_summary>Oral anticoagulant widely use treatment thrombo-embolic disease exert effect block recycle vitamin K. Vitamin K act co-factor posttranslational carboxylation vitamin K-dependent protein osteocalcin matrix-gla protein . It important quantify dose-response relationship interaction vitamin K oral anticoagulant investigate dosage vitamin K interfere oral anticoagulant clinically relevant way .</brief_summary>
	<brief_title>Safety Study Vitamin K2 During Anticoagulation Human Volunteers</brief_title>
	<detailed_description>From K-vitamins , menaquinone-7 identified effective cofactor carboxylation reaction Gla-proteins . In respect important quantify dose-response relationship interaction oral anticoagulant menaquinone-7 . The primary objective study demonstrate menaquinone-7 intake vitamin interfere oral anticoagulant clinically relevant way . Clinically relevant define decrease level anticoagulation would require change oral anticoagulant treatment order stay within target level . Secondary objective study investigate change carboxylation level osteocalcin matrix-gla protein menaquinone-7 supplementation oral anticoagulation treatment period . This demonstrate whether oral anticoagulation menaquinone-7 transport preferentially liver target tissue .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin K 2</mesh_term>
	<mesh_term>Vitamin MK 7</mesh_term>
	<mesh_term>Acenocoumarol</mesh_term>
	<criteria>Healthy male female adult 18 45 year age . Subjects normal body weight height accord BMI &lt; 30 Subject give write consent take part study Subjects ( history ) coagulation disorder Subjects ( history ) metabolic gastrointestinal disease Subjects use ( multi ) vitamin supplement contain vitamin K Subjects present chronic inflammatory disease Subjects use medication 3 month prior study ( e.g . corticoÏŠd treatment , oral anticoagulant ) Subjects use oral anticonception Subject ( history ) soy allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>vitamin K2</keyword>
	<keyword>oral anticoagulation</keyword>
	<keyword>interference</keyword>
	<keyword>level anticoagulation</keyword>
	<keyword>carboxylation level osteocalcin matrix-gla protein</keyword>
</DOC>